Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Peginterferon beta-1a

(Plegridy®)

Peginterferon beta-1a

Drug updated on 9/4/2024

Dosage FormInjection (subcutaneous: 125 mg/0.5 mL, 63 mg/0.5 mL, 94 mg/0.5 mL; Intramuscular: 125 mcg/0.5 mL))
Drug ClassInterferon beta
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Plegridy (peginterferon beta-1a) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • Alemtuzumab, mitoxantrone, natalizumab, and fingolimod were identified as the most effective in reducing relapse rates in RRMS during the first 24 months, with risk ratios (RR) ranging from 0.46 (Alemtuzumab, 95% CI 0.38 to 0.55) to 0.72 (Fingolimod, 95% CI 0.64 to 0.81). One study also highlighted ocrelizumab (RR 0.49, 95% CI 0.40 to 0.61) and peginterferon beta-1a (RR 0.63, 95% CI 0.52 to 0.77) as effective treatments.
  • For preventing disability worsening, mitoxantrone, alemtuzumab, and natalizumab showed significant effectiveness with risk ratios ranging from 0.20 (Mitoxantrone, 95% CI 0.05 to 0.84) to 0.64 (Natalizumab, 95% CI 0.49 to 0.85). One study reported similar effectiveness for alemtuzumab (RR 0.24) in preventing sustained disability progression.
  • Peginterferon beta-1a, while superior to placebo in reducing relapse rates in RRMS patients, was less effective compared to other treatments such as alemtuzumab, ocrelizumab, natalizumab, and fingolimod.
  • Almost all drugs had a higher proportion of participants who withdrew due to adverse events compared to placebo, with mitoxantrone having the highest risk ratio for withdrawal (RR 9.92, 95% CI 0.54 to 168.84) and alemtuzumab the lowest (RR 0.72, 95% CI 0.32 to 1.61).
  • Risk ratios for serious adverse events ranged from 0.85 for natalizumab to 1.25 for teriflunomide 14 mg, indicating a variable safety profile across treatments.
  • There is no population types or subgroups information available in the reviewed studies.